Impact Biomedical (IBO) Non-Current Debt (2023 - 2025)

Impact Biomedical's Non-Current Debt history runs 3 years deep, the most recent figure standing at $22.9 million for Q3 2025.

• Quarterly Non-Current Debt rose 187.05% year-over-year to $22.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $22.9 million (up 187.05% YoY) and the FY2024 annual result came in at $8.9 million, down 26.47% from the prior year.
• Non-Current Debt was $22.9 million for Q3 2025 at Impact Biomedical, up from $22.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $22.9 million in Q3 2025 and bottomed at $8.0 million in Q3 2024.
• A 3-year average of $13.9 million and a median of $10.6 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt fell 26.47% — and 2025, when it surged 187.05%.
• Impact Biomedical's Non-Current Debt stood at $12.1 million in 2023, then decreased by 26.47% to $8.9 million in 2024, then surged by 157.73% to $22.9 million in 2025.
• Business Quant data shows IBO's Non-Current Debt at $22.9 million in Q3 2025, $22.4 million in Q2 2025, and $9.1 million in Q1 2025.